A metastatic lesion is an area of cancer that has spread from its original location to a different part of the body. If breast cancer travels to the liver, the tumor growing in the liver is a metastatic lesion. It’s still made of breast cancer cells, not liver cancer cells, and it’s treated based on where it started. The presence of metastatic lesions is what distinguishes advanced cancer (stage IV) from earlier stages, and it significantly changes both the treatment approach and the outlook.
How Metastatic Lesions Form
Cancer starts in one place, called the primary tumor. For a metastatic lesion to develop somewhere else, tumor cells have to complete a difficult chain of events: detach from the primary tumor, enter the bloodstream or lymphatic system, survive the journey, land in a new organ, and successfully grow in tissue that’s completely different from where they originated.
Most cancer cells that enter the bloodstream don’t survive this process. The ones that do manage to colonize a distant organ aren’t necessarily carrying some special mutation that makes them uniquely dangerous. Large-scale DNA analyses comparing primary tumors to their metastatic counterparts have found that there are hardly any driver mutations exclusively associated with the spread itself. Instead, metastasis appears to be driven by an evolutionary process in which cancer cells interact with the surrounding tissue environment rather than by a single genetic switch being flipped. Metastatic tumors do tend to show higher genomic instability, meaning their DNA is more scrambled overall, but the fundamental biology is remarkably similar to the original tumor.
Why Certain Cancers Spread to Certain Organs
Metastatic lesions don’t appear randomly throughout the body. Each cancer type has preferred destinations. Breast cancer most commonly metastasizes to bone, brain, liver, and lung. Lung cancer favors the adrenal glands, bone, brain, liver, and the opposite lung. Prostate cancer tends to spread to bone, liver, lung, and the adrenal glands. Colon and rectal cancers most often spread to the liver, lungs, and the lining of the abdominal cavity (the peritoneum).
This pattern has been recognized since the 1880s, when a surgeon named Stephen Paget studied over 700 cases of fatal breast cancer and noticed that metastases clustered in specific organs far more than random chance would predict. He proposed what’s still known as the “seed and soil” hypothesis: cancer cells (the seeds) are carried throughout the body, but they can only take root and grow when they land in a compatible environment (the soil). Blood flow patterns play a role too, since the liver filters blood from the colon, colon cancer cells have easy access there. But blood flow alone doesn’t explain the full picture. The chemical and structural environment of the destination organ matters just as much.
Symptoms Depend on Location
A metastatic lesion often produces symptoms related to the organ it’s growing in, not the organ where the cancer started. This is one reason metastatic cancer can be confusing. Someone with no lung symptoms might develop back pain and learn they have lung cancer that has spread to the spine.
Bone metastases commonly cause deep, persistent pain that worsens over time and may lead to fractures in bones weakened by the tumor. Brain metastases can produce headaches, seizures, vision changes, or difficulty with balance and coordination. Liver metastases may cause abdominal swelling, jaundice (yellowing of the skin), nausea, or unexplained weight loss. Lung metastases often show up as a persistent cough, shortness of breath, or chest discomfort.
In some cases, metastatic lesions are discovered before the primary cancer is identified. A patient might seek care for a hip fracture, for example, and imaging reveals a bone lesion that turns out to be metastatic prostate cancer.
How Metastatic Lesions Are Detected
Doctors use several imaging tools to find metastatic lesions, and the choice depends on which organ is being examined.
CT scans are the workhorse for scanning the chest, abdomen, and pelvis. They’re fast and widely available, making them a standard part of cancer staging. PET/CT scans go a step further by using a radioactive sugar tracer to highlight areas of unusually high metabolic activity, which is characteristic of cancer cells. This makes PET/CT especially useful for detecting small metastatic lesions that a standard CT might miss, or for surveying the entire body at once.
MRI provides the most detailed soft tissue images and is the preferred tool for evaluating brain metastases and bone marrow involvement. For bone lesions specifically, radiologists look for areas where normal bone marrow has been replaced by tumor tissue. A specialized MRI technique called diffusion-weighted imaging can help distinguish true metastatic lesions from benign changes in bone marrow that might otherwise look suspicious.
Biopsies, where a small tissue sample is taken from the lesion and examined under a microscope, confirm whether the cells match the primary cancer. This step is critical because it determines what type of treatment will work.
What Metastatic Lesions Mean for Staging
The standard cancer staging system uses three categories: T (tumor size), N (lymph node involvement), and M (distant metastasis). The M category is binary in its most basic form. M0 means no distant spread has been found. M1 means cancer has spread to other parts of the body. Some cancer types subdivide M1 further, into M1a, M1b, or M1c, based on how many organs are affected or which specific sites are involved.
Any cancer classified as M1 is considered stage IV, regardless of how small the primary tumor is or how few lymph nodes are involved. This single factor, the presence of metastatic lesions, overrides everything else in determining the overall stage.
How Treatment Differs From Earlier Stages
When cancer is still localized, treatment typically aims to remove or destroy it entirely through surgery, radiation, or both. Once metastatic lesions are present, the strategy shifts. Because cancer cells have already demonstrated the ability to travel and grow in distant organs, local treatments alone can’t address the full problem.
Systemic therapies, treatments that travel through the bloodstream and reach cancer cells wherever they are, become the foundation. These include chemotherapy, immunotherapy, targeted therapy, and hormone therapy, depending on the cancer type. The goal with systemic treatment is to slow or stop the growth of metastatic lesions throughout the body.
That said, local treatments still play a role in metastatic disease. If only a small number of lesions are present in limited locations (sometimes called oligometastatic disease), surgery or focused radiation to those specific spots can sometimes provide meaningful benefit. Radiation can also be used to relieve symptoms from metastatic lesions, such as shrinking a bone metastasis that’s causing pain or a brain metastasis that’s pressing on surrounding tissue.
Survival Rates and What Shapes Them
The presence of metastatic lesions substantially changes survival statistics. Prostate cancer illustrates this clearly: when the disease is still confined to the prostate gland, the five-year relative survival rate is essentially 100%. Once it has metastasized to distant organs, that number drops to about 40%. Similar gaps exist across most cancer types.
These numbers represent averages across large populations, and individual outcomes vary widely based on factors like the specific cancer type, how many metastatic lesions are present, which organs are involved, how the cancer responds to treatment, and the person’s overall health. Some metastatic cancers respond remarkably well to newer treatments like immunotherapy, while others remain more difficult to control. A single small metastatic lesion in one organ carries a very different prognosis than widespread disease across multiple sites.
Metastatic lesions also behave differently over time depending on their origin. Metastatic thyroid cancer, for instance, can sometimes be managed for many years. Metastatic pancreatic cancer, on the other hand, tends to progress much more quickly. The biology of the original cancer still drives the behavior of its metastatic lesions, which is why treatment always targets the cancer type rather than the organ where the lesion happens to be sitting.